Select Language
VEGF R2
VEGF R2 Overview
| English Name | Vascular endothelial growth factor receptor 2 | Approved Drugs | 18 |
| Drugs in Clinical Trials | 61 | Target Synonym | EC:2.7.10.1，EC 2.7.10，VEGFR2，KDR，Vascular endothelial growth factor receptor 2，Fetal liver kinase 1，Kinase insert domain receptor，Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase)，Protein-Tyrosine Kinase Receptor Flk-1，FLK1，Tyrosine Kinase Growth Factor Receptor，Fetal Liver Kinase-1，Soluble VEGFR2，CD309 Antigen，EC 2.7.10.1，VEGFR-2，CD309，VEGFR，FLK-1，Vascular Endothelial Growth Factor Receptor-2 |
| Highest Development Stage | Approved | ||
| English Name | Vascular endothelial growth factor receptor 2 |
| Target Synonym | EC:2.7.10.1，EC 2.7.10，VEGFR2，KDR，Vascular endothelial growth factor receptor 2，Fetal liver kinase 1，Kinase insert domain receptor，Kinase Insert Domain Receptor (A Type III Receptor Tyrosine Kinase)，Protein-Tyrosine Kinase Receptor Flk-1，FLK1，Tyrosine Kinase Growth Factor Receptor，Fetal Liver Kinase-1，Soluble VEGFR2，CD309 Antigen，EC 2.7.10.1，VEGFR-2，CD309，VEGFR，FLK-1，Vascular Endothelial Growth Factor Receptor-2 |
| Approved Drugs | 18 |
| Drugs in Clinical Trials | 61 |
| Highest Development Stage | Approved |
VEGF R2 Product List
- Product Category
Protein (9)Cell (1)
- Product Status
Launched (10)
- Species
Human (7)Rhesus macaque (1)Mouse (2)
- Tag
His Tag (4)Strep Tag (1)His Tag & Avi Tag (2)Mouse IgG Fc Tag (1)Fc Tag (1)- (1)
- Conjugate
Unconjugated (5)Biotin-labeled (2)- (1)PE Labeled (1)APC Labeled (1)
Add to Cart
Total: 10
- 1
VEGF R2 Background
Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.
VEGF R2 Synonyms
KDR,CD309,FLK1,VEGFR,VEGFR2
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Simmitinib hydrochloride | SOMCL-15-290 | Phase 3 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Breast Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Inlecitug | Phase 3 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| BC-001 | BC001; BC-001 | Phase 3 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| XY-0206 | XY-0206 | Phase 3 Clinical | Nanjing University Of Chinese Medicine | Leukemia, Myeloid, Acute; Solid tumours | Details |
| KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Adenocarcinoma; Digestive System Neoplasms; Esophageal Squamous Cell Carcinoma; Hematologic Neoplasms; Neoplasm Metastasis; Sarcoma, Ewing; Solid tumours; Thymus Neoplasms | Details |
| Cediranib | AZD2171; AZD-2171; NSC-732208 | Phase 3 Clinical | Astrazeneca Plc | Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenocarcinoma, Mucinous; Angioimmunoblastic T-cell Lymphoma; Ascites; Astrocytoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Carcinosarcoma; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Ependymoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hepatic Insufficiency; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypopharyngeal Neoplasms; Intraocular Lymphoma; L | Details |
| Sitravatinib | MG-516; MG-91516; MGCD-516; IND-155305; MGCD-0516 | Phase 3 Clinical | Mirati Therapeutics Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Hepatic Insufficiency; Kidney Neoplasms; Liposarcoma; Lung Diseases; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Oral Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Ureteral Neoplasms; Uterine Cervical Neoplasms; Uveal melanoma | Details |
| Simmitinib | SYHA-1817 | Phase 3 Clinical | CSPC Pharmaceutical Group Ltd | Biliary Tract Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Stomach Neoplasms | Details |
| Axitinib intravitreal implant (Ocular Therapeutix) | OTX-TKI | Phase 3 Clinical | Ocular Therapeutix Inc | Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration | Details |
| Pulocimab | AK-109; AK109 | Phase 3 Clinical | Adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Recombinant Anti-VEGFR2 Fully Human Monoclonal Antibody(Jingyitaixiang Technology Development) | JY-025 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd, Beijing Jingyitaixiang Technology Development Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| MSB-0254 | MSB-0254 | Phase 2 Clinical | Suzhou Transcenta Therapeutics Co Ltd | Solid tumours | Details |
| AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pulmonary Fibrosis; Solid tumours; Urinary Bladder Neoplasms | Details |
| (-)-Epigallocatechin gallate | AB-4166 | Phase 2 Clinical | Charite Universitaetsmedizin Berlin | Alzheimer Disease; Colonic Neoplasms; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Frailty; Glaucoma, Open-Angle; Huntington Disease; Hypertension; Idiopathic Pulmonary Fibrosis; Inflammation; Insulin Resistance; Leukemia; Liver Cirrhosis; Lung Diseases, Interstitial; Multiple Sclerosis, Relapsing-Remitting; Muscular Dystrophy, Duchenne; Neoplasms; Obesity; Ocular Hypertension; Papillomavirus Infections; Parkinson Disease; Peripheral Nervous System Diseases; Prostatic Neoplasms; Uterine Cervical Diseases | Details |
| Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 2 Clinical | Advenchen Laboratories Nanjing Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Thymus Neoplasms | Details |
| VEGFR2 peptide vaccine (VAXIMM) | VXM-01 | Phase 2 Clinical | Merck Serono | Colorectal Neoplasms; Glioblastoma; Pancreatic Neoplasms | Details |
| Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
| Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Transitional Cell; Cholangiocarcinoma; Solid tumours; Stomach Neoplasms; Urogenital Neoplasms | Details |
| OT-202 | OT 202; OT-202 | Phase 2 Clinical | Ocumension (Hong Kong) Ltd | Xerophthalmia | Details |
| OTP-01 | OTP-01 | Phase 2 Clinical | Ottimo Pharma Ltd | Neoplasms; Solid tumours | Details |
| Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 2 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Respiratory Tract Diseases | Details |
| BR-55 | BR-55; BR55 CEUS | Phase 2 Clinical | Sonus Pharmaceuticals Ltd | Contrast agents; Diagnostic agents; Inflammation; Neoplasms; Ovarian Neoplasms | Details |
| Axitinib Implant（Aerie） | AR-14034 SR; AR-14034 | Phase 2 Clinical | Aerie Pharmaceuticals Inc | Macular Degeneration | Details |
| K-13 | Phase 2 Clinical | Shanghai Yifeng Biotechnology Co Ltd | Neoplasms; Solid tumours | Details | |
| Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
| Tosposertib phosphate | TU-2218; NCE401; NCE-401 | Phase 2 Clinical | TiumBio Co Ltd | Idiopathic Pulmonary Fibrosis; Solid tumours | Details |
| VEGFR-1/2 peptide vaccine (Keio University) | Phase 2 Clinical | Keio University | Brain Neoplasms; Glioma; Neurofibromatoses | Details | |
| Gersizangitide | AXT-107 | Phase 2 Clinical | AsclepiX Therapeutics Inc | Diabetic macular oedema; Macular Degeneration | Details |
| KDR2-2 | Phase 2 Clinical | Guangzhou Huiborui Biomedical Technology Co Ltd | Corneal Neovascularization; Glaucoma, Neovascular; Neovascularization, Pathologic | Details | |
| KHK-4951 | Phase 2 Clinical | Kyowa Kirin | Diabetic macular oedema; Macular Degeneration; Macular Edema; Wet Macular Degeneration | Details | |
| CEP-11981 | ESK-981; CEP-11981; SSR-106462; BOL-303213X | Phase 2 Clinical | Sanofi | Adenoma, Islet Cell; Bone metastases; Carcinoma, Adenosquamous; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| Axitinib injectable suspension (Clearside Biomedical) | CLS-1002; CLS-011-A; CLS011A; CLS-AX | Phase 2 Clinical | Clearside Biomedical Inc | Macular Degeneration | Details |
| Hydroxychloroquine/Sorafenib | Phase 2 Clinical | Vg Life Sciences | Ovarian Neoplasms; Solid tumours | Details | |
| EDP317 | ACTB-1003; EOC-317; EDP-317 | Phase 1 Clinical | Act Biotech Inc, Bayer AG | Biliary Tract Neoplasms; Breast Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| Kanitinib | CX-1003 | Phase 1 Clinical | Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd | Solid tumours | Details |
| VEGFR2 peptide vaccine (Tokyo University) | Phase 1 Clinical | University Of Tokyo | Pancreatic Neoplasms | Details | |
| Brivanib Alaninate | ZL-2301; BMS-540215; BMS-582664 | Phase 1 Clinical | Bristol-Myers Squibb Company | Adenocarcinoma, Clear Cell; Asthma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastrointestinal Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Pulmonary Disease, Chronic Obstructive; Rectal Neoplasms; Sarcoma; Solid tumours; Uterine Cervical Neoplasms | Details |
| Ramucirumab biosimilar (Henlius) | HLX-12 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms | Details | |
| Timtraxanib | AVI-3207 | Phase 1 Clinical | Avixgen | Macular Degeneration | Details |
| Pamufetinib | TAS-115 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd | Neoplasms | Details |
| nintedanib (Avalyn Pharma) | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| Ramucirumab biosimilar (Sichuan Kelunbotai Biopharmaceutical) | Phase 1 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | Details | |
| Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Jilin Boda Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd | Neoplasms | Details |
| Nintedanib Esylate Inhalation Powder(Cspc) | Phase 1 Clinical | Cspc-Nbp Pharmaceutical Co Ltd | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| JSKN-027 | JSKN027; JSKN-027 | Phase 1 Clinical | Alphamab Oncology | Neoplasms; Solid tumours | Details |
| DPH-001 | DPH-001; DPH001 | Phase 1 Clinical | Disruptive Pharma AB | Details | |
| QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
| Ramucirumab biosimilar (Klus Pharma) | A168; A-168 | Phase 1 Clinical | Klus Pharma Inc | Details | |
| MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
| ETN-101 | ETN101; ETN-101; MBP-11901 | Phase 1 Clinical | Etnova Therapeutics Corp | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| RP-904 | Phase 1 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Solid tumours | Details | |
| RA1115-B1 | RA1115-B1 | Phase 1 Clinical | Suzhou Raymon Pharmaceuticals Co Ltd | Diabetic macular oedema; Macular Degeneration; Wet Macular Degeneration | Details |
| PZ-1 | PZ-1 | Phase 1 Clinical | Chongqing University Of Arts And Sciences | Solid tumours | Details |
| ICP-033 | ICP-033 | Phase 1 Clinical | Beijing Innocare Pharma Tech Co Ltd | Solid tumours | Details |
| PAN-90806 | OSI-632; CP-632; CP-547632; PAN-90806 | Phase 1 Clinical | Osi Pharmaceutical, Pfizer Inc | Abdominal Neoplasms; Diabetic Retinopathy; Fallopian Tube Neoplasms; Lung Neoplasms; Macular Degeneration; Ovarian Neoplasms; Peritoneal Neoplasms; Wet Macular Degeneration | Details |
| LMV-12(HE003) | LMV-12(HE003) | Phase 1 Clinical | Nanchang Hongyi Technology Co Ltd | Solid tumours | Details |
| Metatinib Trometamol | BMS-817378; SIM-817378 | Phase 1 Clinical | Bristol-Myers Squibb Company | Colorectal Neoplasms; Liver Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Nanjing Nadingfei Pharmaceutical Technology Co Ltd, Shijiazhuang No 4 Pharmaceutical Co Ltd | Liver Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| FNX-006 | FNX-006 | Phase 1 Clinical | Chengdu Fannuoxi Biomedical Technology Co Ltd, Sichuan University | Melanoma; Triple Negative Breast Neoplasms | Details |
| Sorafenib tosylate (Bio-Synectics) | BS-104 | Clinical | Bio-Synectics Inc | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Bile Duct Diseases; Bone Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Craniopharyngioma; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastroesophageal Junction Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Head and Neck Neoplasms; Hepatic Insufficiency; Leiomyosarcoma; Liver Dysfunction; Lung Diseases, Interstitial; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Medullary thyroid cancer (MTC); Melanoma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Neuroendocrine Tumors; Osteoma; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Sarcoma, Alveolar Soft Part; Sarcoma, Synovial; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Thoracic Neoplasms; Thyroid Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Lenvatinib Mesilate | E-7080; MK-7902; ER-203492-00 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Follicular; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Hepatic Insufficiency; Liver Diseases; Liver Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Paraganglioma; Pheochromocytoma; Renal Insufficiency; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Uterine Cervical Neoplasms | Details |
| Axitinib | PF-01367866; AG-13736; AG-013736 | Approved | Pfizer Inc | 英立达, Inlyta | United States | Carcinoma, Renal Cell | Pf Prism Cv | 2012-01-27 | Adenocarcinoma; Adrenal Cortex Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Ductal; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Glioblastoma; Hepatic Insufficiency; Kidney Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Melanoma; Mesothelioma; Myelodysplastic Syndromes; Nasopharyngeal Neoplasms; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Paraganglioma; Pheochromocytoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Uveal melanoma | Details |
| Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Adenocarcinoma; Adenoma; Bile Duct Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucagonoma; Hemangiosarcoma; Insulinoma; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Melanoma; Meningioma; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Sarcoma; Sarcoma, Ewing; Solid tumours; Somatostatinoma; Stomach Neoplasms; Thymoma; Thyroid Neoplasms | Details |
| Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim International Gmbh | 2014-10-15 | Adenocarcinoma, Clear Cell; Appendiceal Neoplasms; Asbestosis; Astrocytoma; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Endometrial Stromal Tumors; Esophageal Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Gliosarcoma; Hepatic Insufficiency; Idiopathic Pulmonary Fibrosis; Leukemia, Myeloid, Acute; Lung Diseases, Interstitial; Mesothelioma; Multiple Myeloma; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Pulmonary Fibrosis; Radiation Pneumonitis; Rejection of lung transplantation; Sarcoma; Scleroderma, Systemic; Silicosis; Small Cell Lung Carcinoma; Solid tumours; systemic sclerosis-associated interstitial lung disease; Telangiectasia, Hereditary Hemorrhagic; Uterine Neoplasms | Details |
| Vorolanib | CM-082; X-82; EYP-1901; XV-615 | Approved | Tyrogenex Inc | 伏美纳, DURAVYU™ | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Choroidal Neovascularization; Diabetic macular oedema; Diabetic Retinopathy; Eye Diseases; Gastroesophageal Junction Neoplasms; Kidney Neoplasms; Leukemia, Myeloid, Acute; Macular Degeneration; Melanoma; Neoplasms; Pancreatic Neoplasms; Retinal Degeneration; Retinal Diseases; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Wet Macular Degeneration | Details |
| Tivozanib | KRN-951; KHK-4951; KHK4951; UNII-172030934T; ASP-4130; Kil-8951; AV-951 | Approved | Kyowa Hakko Kirin Co Ltd | Fotivda, FOTIVDA | EU | Carcinoma, Renal Cell | Recordati Netherlands BV | 2017-08-24 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Cholangiocarcinoma; Colorectal Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Hepatic Insufficiency; Metastatic breast cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Solid tumours; Triple Negative Breast Neoplasms; Wet Macular Degeneration | Details |
| Apatinib Mesylate | YN-968D1 | Approved | Advenchen Laboratories Llc | 艾坦, Aitan | Mainland China | Stomach Neoplasms | Jiangsu shengdi Medicine Co Ltd | 2014-10-17 | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Esophageal Neoplasms; Esthesioneuroblastoma, Olfactory; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Metastatic breast cancer; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Ripretinib | DCC-2618 | Approved | Deciphera Pharmaceuticals | Qinlock, 擎乐 | United States | Gastrointestinal Stromal Tumors | Deciphera Pharmaceuticals Llc | 2020-05-15 | Gastrointestinal Stromal Tumors; Mastocytosis, Systemic; Neoplasms | Details |
| Ramucirumab | IMC-1121; IMC-1C11; LY-3009806; IMC-1121-B; BLA-125477 | Approved | Dyax Pharma | Cyramza | United States | Gastrointestinal Stromal Tumors | Eli Lilly And Company | 2014-04-21 | Adenocarcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Stromal Tumors; Melanoma; Metastatic breast cancer; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urologic Neoplasms | Details |
| Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell | Cppi Cv | 2006-01-26 | Abdominal Neoplasms; Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenocortical Carcinoma; AIDS-Related Complex; Amyloidosis; Angioimmunoblastic T-cell Lymphoma; Astrocytoma; Barrett Esophagus; Brain metastases; Brain Neoplasms; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Carcinoma, Acinar Cell; Carcinoma, Adenoid Cystic; Carcinoma, Adenosquamous; Carcinoma, Embryonal; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Choriocarcinoma; Chronic eosinophilic leukemia (CEL); Cognition Disorders; Colorectal Neoplasms; Diabetic macular oedema; Endodermal Sinus Tumor; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Fibrosarcoma; Gastrointestinal Stromal Tumors; Germinoma; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Hemangi | Details |
| Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Adenocarcinoma, Follicular; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Embryonal; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Chondrosarcoma; Chondrosarcoma, Extraskeletal Myxoid; Choriocarcinoma; Colorectal Neoplasms; Dermatofibrosarcoma; Endodermal Sinus Tumor; Epistaxis; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gastrinoma; Gastroenteropancreatic neuroendocrine tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Germinoma; Glioblastoma; Glioma; Gliosarcoma; Glucagonoma; Hemangiosarcoma; Herpes Genitalis; Herpes Simplex; HIV Infections; Hormone-Resistant Prostate Neoplasms; Insulinoma; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Lung Neoplasms; Lymphoma; Macular Degeneration; Medullary thyroid cancer (MTC); Melanoma; Mesothelioma; Multiple Endocrine Neoplasia T | Details |
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin | Details |
| Fruquintinib | HMPL-013; TAK-113 | Approved | FRUZAQLA, Aiyoute, Elunate, 爱优特 | Mainland China | Colorectal Neoplasms | Hutchison Medipharma Ltd | 2018-09-04 | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hepatic Insufficiency; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Renal Insufficiency; Sarcoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details | |
| Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Abdominal Neoplasms; Adenocarcinoma; Angioimmunoblastic T-cell Lymphoma; Astrocytoma; Bile Duct Neoplasms; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Cholangiocarcinoma; Colonic Neoplasms; Esophageal Neoplasms; Facial Neoplasms; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gallbladder Neoplasms; Gastrinoma; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Gliosarcoma; Glucagonoma; Head and Neck Neoplasms; Heart Arrest; Hemangiosarcoma; Hepatopulmonary Syndrome; Histiocytoma, Malignant Fibrous; Hypertension, Portal; Hypopharyngeal Neoplasms; Insulinoma; Kidney Diseases; Kidney Neoplasms; Laryngeal Diseases; Laryngeal Neoplasms; Leiomyosarcoma; Leukemia, Basophilic, Acute; Leukemia, Eosin | Details |
| Vandetanib | AZD-6474; CH-331; ZD-6474 | Approved | Astrazeneca Plc | Zactima, Caprelsa | United States | Carcinoma, Neuroendocrine; Thyroid Neoplasms | Genzyme Corp | 2011-04-06 | Abdominal Neoplasms; Adenocarcinoma; Ampullary Carcinoma; Anus Neoplasms; Astrocytoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Diffuse Intrinsic Pontine Glioma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Glioma; Gliosarcoma; Head and Neck Neoplasms; Intestinal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Lymphoma; Lymphoproliferative Disorders; Medullary thyroid cancer (MTC); Mesothelioma; Metastatic breast cancer; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Oligodendroglioma; Ovarian Neoplasms; Pancreatic Neoplasms; Paraganglioma; Peritoneal Neoplasms; Pheochromocytoma; Pleural Effusion; Precancerous Co | Details |
| Famitinib Malate | SHR-1020 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾比特 | Mainland China | Uterine Cervical Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2025-05-27 | Adenocarcinoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic neuroendocrine tumors (pNET); Small Cell Lung Carcinoma; Solid tumours; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Leukemia, Mast-Cell | Novartis Pharmaceuticals Corp | 2017-04-28 | Hematologic Neoplasms; Hepatic Insufficiency; Leukemia; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mastocytosis; Mastocytosis, Systemic; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland